Glutamine supplementation for cystic fibrosis

Not Applicable

Completed

• Conditions: Cystic fibrosis; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN22534872
• Lead Sponsor: niversity of Nottingham (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-12-21
• Last Update Posted: 3 July 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

1. Over 14 years old, male and female
2. Forced expiratory volume in one second (FEV1) greater than 40% predicted or receive regular nebulised saline treatment
3. Colonisation with Pseudomonas

Exclusion Criteria

1. Current pregnancy or breastfeeding
2. Recent pulmonary exacerbation in past month
3. Lung transplant
4. Recently diagnosed or uncontrolled diabetes
5. Cirrhosis or severe liver failure
6. Initiation of new pulmonary therapies in the past month

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in inflammatory markers in induced sputum, measured at baseline and after eight weeks.

Secondary Outcome Measures

Name	Time	Method
1. FEV1<br>2. Serum C-reactive protein (CRP)<br>3. Infectious load of Pseudomonas<br>4. Systemic blood neutrophil activity<br>5. Jensen clinical score<br><br>All outcomes measured at baseline and after eight weeks.